7th WBMT WORKSHOP

Commemorating Completion of 1200 Transplants at AFBMTC/NIBMT

Feb 2022

What are you waiting for?

Join this historical event.

Days
Hours
Minutes
Seconds

Welcome

Dear friends and colleagues,

On behalf of the organizing committee, we welcome you all to the 7th Worldwide Network for Blood and Marrow Transplantation (WBMT) Workshop in Islamabad, Pakistan. This represents a historical event involving global experts, who are known for their efforts to improve health care access and treatment throughout the World. This workshop is a continuation of events pioneered by WBMT, aiming at helping countries with restricted transplant resources and activity.
The WBMT is incorporated as a non-profit organization for educational, scientific and philanthropic purposes under the laws of Switzerland and is located in Bern. The WBMT promotes excellence in stem cell transplantation (SCT), stem cell donation, cellular therapy (CT) and accreditation as well as access to SCT worldwide through collaboration of existing international societies using coordination, communication and advocacy. The purpose of this cooperation is to engage exclusively in charitable, scientific, and educational activities and endeavors including specifically, but not limited to, promoting and fostering among the many scientific and clinical disciplines, the exchange and diffusion of information and ideas relating to SCT and CT and encouraging investigations on these matters. The focus of the Network is to advance the field of SCT and CT in collaboration with its member societies. The WBMT is providing an excellent platform where different specialists are working together offering their decades of experience and expertise to develop and improve transplant activities in resource restricted countries.
This Workshop will include delegates from Eastern Mediterranean region, North America, South America, Asia Pacific , Europe and Africa who will all be involved in discussion and guidance on establishing transplantation program, donor selection, coordination among transplant societies and centres, transfusion support, accreditation system, cell processing and quality assurance. Regional experts will be presenting transplant activities and local health authorities will be engaged to sensitize them about importance of HSCT as a curative therapy for a variety of malignant and non-malignant disorders. The local organization of this event is done by Armed Forces Bone Marrow Transplant Centre / National Institute of Blood and Marrow Transplant (AFBMTC/NIBMT), located in Rawalpindi, Pakistan. Established in 2001, AFBMTC/NIBMT is the only dedicated transplant centre of the country with capability of performing more than 150 allogeneic transplants/year. AFBMTC/NIBMT is also the only centre of Pakistan to have a cellular therapy programme and an in house mesenchymal stem cell culture facility since 2015.
We are delighted to welcome our friends and participants from all over the world to this prestigious event. We hope that this event will increase knowledge, skill, networking with new friends and colleagues and last but not the least, to enjoy the Pakistani culture and hospitality.

Prof. Dr. H. Greinix

WBMT President Committee

Prof. Dr. Q. Chaudhry

President of the local Organizing

hildegard-greinix

WBMT President Committe

Prof. Dr. H. Greinix
WBMT President Committee

01- Prof Dr Qamar Un Nisa Ch

President of the local organizing

Prof Dr Qamar Un Nisa Chaudhry
Professor of Clinical Haematology & BMT Physician
AFBMTC/NIBMT, Rawalpindi - PK

Secretary

Dr Raheel Iftikhar
Consultant Clinical Hematologist & BMT Physician
AFBMTC/NIBMT, Rawalpindi -

HOSTED BY

AFBMTC/NIBMT

Rawalpindi – Pakistan

\\ Speakers & Panelists //

Adriana Seber

Adriana Seber

Chair, Speaker, Panelist

dr-amirali-hamidieh

Amir Ali Hamidieh

Speaker, Panelist

Bishesh Poudyal

Bishesh Poudyal

Speaker, Panelist

doctor

Carmen Bonfim

Chair, Speaker

doctor

Cristobal Furtos

Speaker, Panelist

Danial Weisdorf

Danial Weisdorf

Speaker, Panelist, Moderator

doctor

Dietger Niederwieser

Chair, Speaker Panelist

doctor

Feras Alfraih

Chair, Panelist

Helen Baldomero

Helen Baldomero

Speaker, Panelist

hildegard-greinix

Hildegard Greinix

Chair, Speaker, Panelist

Javid Gaziev

Javid Gaziev

Speaker, Panelist

Jeff Szer

Jeff Szer

Panelist, Moderator

dr. marcelo pasquini

Marcelo Pasquini

Speaker, Panelist, Moderator

02- Dr Mehreen Ali Khan

Mehreen Ali Khan

Speaker, Panelist

Mickey Koh

Mickey Koh

Speaker, Panelist, Moderator

Minako IIDA

Minako IIDA

Speaker, Panelist

Mohiuddin Khan

Speaker, Panelist

Murtadha Al-Khabori

Murtadha Al-Khabori

Speaker, Panelist

prof. dr. nina worel

Nina Worel

Chair, Speaker, Panelist

Paul Eldridge

Paul Eldridge

Chair, Speaker, Panelist

01- Prof Dr Qamar Un Nisa Ch

Qamar Un Nisa Ch.

Chair, Panelist

Raheel Iftikhar

Chair, Speaker

41 - Salman Naseem Adil

Salman N. Adil

Chair, Panelist

Sebastian Galeano

Sebastian Galeano

Chair, Speaker

36 - Shahrukh K Hashmi

Shahrukh K. Hashmi

Speaker, Panelist, Moderator

Syed-Ahmed-144

Syed Osman Ahmed

Speaker, Panelist

doctor

Yoshihisa Kodera

Chair, Panelist

doctor

Yoshiko Atsuta

Chair, Panelist

\\ Panelists //

M Ayaz Mir

M Ayaz Mir

Panelist

41 - Salman Naseem Adil

Salman N. Adil

Chair, Panelist

\\ Moderators //

40 - Ghassan Umair Shamshad

Ghassan Umair Shamshad

Consultant Haematologist

02- Dr Mehreen Ali Khan

Mehreen Ali Khan

Consultant Haematologist

Nighat Shahbaz

Nighat Shahbaz

Consultant Haematologist

Raheel Iftikhar

Classified Medical Specialist & BMT Physician

Abstracts
Registrations
Sessions
Speakers/Panelists

\\ Workshop PROGRAM //

Day 1 - Friday, 25 Feb 2022

\\ Symposium PROGRAM //

Day 1 - Friday, 25 Feb 2022

Session-I Plenary Session Day 1: February 25, 2022
Session Time Chair(s)
0830-1005 hrs
(PST/GMT+5)
Qamar Un Nisa Chaudhry, Pakistan Hildegard Greinix, Austria
WHO Representative in Pakistan Raheel Iftikhar, Pakistan
0830-0920 hrs Inaugural Talks
  Qamar Un Nisa Chaudhry, Pakistan Nigar Johar / Faisal Sultan, Pakistan Hildegard Greinix, Austria
  Shinichiro Okamoto, Japan Naeem A. Chaudhri, Saudi Arabia
0920-0950 hrs WHO – Global Perspective of HSCT
Efstratios Chatzixiros, Switzerland
0950-1005 hrs Pakistan’s health care system with focus on therapy of Aplastic Anemia
Parvez Ahmed, Pakistan
1005-1020 hrs Coffee Break
1020-1140 hrs Regional Transplantation Activities Tahir Sultan Shamsi (Pakistan)
Murtadha Al-khabori (Oman)
Amir Ali Hamidieh (Iran)
Javid Gaziev (Qatar)
Marwan Shaheen (Saudi Arabia)
Mohiuddin Khan (Bangladesh)
Bishesh Poudyal (Nepal)
Shahrukh Hashmi (UAE)
1140-1200 hrs Explanation of Program Agenda
Sebastian Galeano, Uruguay
1200-1300 hrs Lunch Break
Session – IPST: 1700-1300Add to Calendar
Plenary Session
Add to Calendar
Chair(s) 0830-1005 hrs (PST/GMT+5)

Qamar Un Nisa Ch.

AFBMTC/NIBMT

Rawalpindi – PK

Hildegard Greinix

Austria

Raheel Iftikhar

AFBMTC/NIBMT
Rawalpindi – PK

Inaugural Talks

0830-0920 hrs

Qamar Un Nisa Ch.

AFBMTC/NIBMT

Rawalpindi – PK

Shinichiro Okamoto

Japan

Nigar Johar

Pakistan

Faisal Sultan

Pakistan

Hildegard Greinix

Austria

Naeem A. Chaudhri

Saudi Arabia

Coffee Break

1005-1020 hrs
Topic

Regional Transplantation Activities

Tahir Sultan Shamsi

National Institute of Blood Diseases & BMT

Karachi – PK

Murtadha Al-khabori

Oman

Amir Ali Hamidieh

Iran

Javid Gaziev

Qatar

Marwan Shaheen

Saudi Arabia

Mohiuddin Khan

Bangladesh

Bishesh Poudyal

Nepal

Shahrukh Hashmi

UAE

Lunch Break

1200-1300 hrs

1020-1140 hrs

Day 2 - saturday, 31 july 2021

EST: 0800-0900 PST: 1700-1800

Session – IV

Hematological Malignancies

Topic

Lymphoma

Moderator

Usman Ahmad

SKMCH & RC
Lahore – PK

Speaker & Panelist

Tanya Siddiqi

City of Hope National Medical Center

Duarte, CA – USA

M Salman Faisal (Speaker only)

The Ohio State University

Columbus, OH – USA

Panelist 

Farrukh T. Awan

UT Southwestern Medical Center

Dallas, TX – USA

Vasia Ahmed

Chicago Ridge, IL

Kamran Rashid

Rashid Nursing Home & Cancer Center

Rawalpindi – PK

EST: 0900-1030 PST: 1800-1930

Session – V

Hematological Malignancies

Topic

Lymphoma & CAR-T

Moderator

Azhar Shafi

Shifa International Hospital
Islamabad – PK

Speaker & Panelist

Sairah Ahmed

MD Anderson Cancer Center

Houston, TX – USA

Jasmine M. Zain

Toni Stephenson lymphoma centre at city of hope, Duarte, CA USA

Panelist 

Abdullah M. Khan

The Ohio State University

Columbus – USA

Syed Waqas Imam Bokhari

SKMCH & RC

Lahore – PK

EST: 1030-1130 PST: 1930-2030

Session – VI

Hematological Malignancies

Topic

Myeloproliferative Neoplasms

Moderator

Mehreen Ali Khan

AFBMTC/NIBMT
Rawalpindi – PK

Speaker & Panelist

Naseema Gangat

Mayo Foundation for Medical Education & Research

Rochester, FL – USA

Panelist 

Haris Ali

City of Hope National Medical Center

Duarte, CA – USA

Irum Khan

University of Illinois Hospital

Chicago – IL

M Usman Shaikh

The Aga Khan University Hospital

Karachi – PK

Day 3 - sunday, 01 august 2021

EST: 0800-0840 PST: 1700-1740

Session – VII

Benign Hematology

Topic

Bone Marrow Failure Syndromes

Moderator

Raheel Iftikhar

AFBMTC/NIBMT
Rawalpindi – PK

Speaker & Panelist

Qamar Un Nisa Ch.

AFBMTC/NIBMT

Rawalpindi – PK

Panelist 

Parvez Ahmed

Quaid-e-Azam International Hospital

Islamabad – PK

Salman Naseem Adil

The Aga Khan University Hospital

Karachi – PK

Syed Osman Ahmed

KFSHRC · Oncology Center

Riyadh – KSA

EST: 0840-0940 PST: 1740-1840

Session – VIII

Multiple Myeloma

Topic

Multiple Myeloma & Amyloidosis

Moderator

Jahanzeb Ur Rahman

CMH

Bahawalpur

Speaker

Hamza Hashmi

Hollings Cancer Center – MUSC Health

Charleston, SC – USA

Panelist 

Saad Usmani

UNC-CH School of Medicine

Chapel Hill, NC – USA

Zeba Aziz

Hameed Latif Hospital

Lahore – PK

Maria Chaudhry

Ohio State University Wexner Medical Center Columbus Ohio, USA

Syed Abbas Ali

The Johns Hopkins University School of Medicine

Baltimore, MD – USA

M Ayaz Y. Mir

Shifa International Hospital

Islamabad – PK

EST: 0940-1030 PST: 1840-1930

Session – IX

Benign Hematology

Topic

Hemoglobinopathies

Moderator

Muhammad Farhan

Gambat Institute of Medical Scienecies Gambat – PK

Speaker & Panelist

Damiano Rondelli

University of Illinois Hospital

Chicago, IL – USA

Panelist 

Hatoon Ezzat

St. Paul’s Hospital

Vancouver, Canada

Tariq Mahmood Satti

Shifa International Hospital

Islamabad – PK

Tariq Ghafoor

AFBMTC/NIBMT

Rawalpindi – PK

EST: 1030-1130 PST: 1930-2030

Session – X

Transplantation & CAR-T Cell

Topic

Complications of HSCT

Moderator

Natasha Ali

The Aga Khan University Hospital Karachi – PK

Speaker & Panelist

Shahrukh K. Hashmi

Mayo Foundation for Medical Education and Research

Rochester, Minnesota – USA

Panelist 

Farrukh T. Awan

UT Southwestern Medical Center

Dallas, TX – USA

Syed Kamran Mahmood

AFBMTC/NIBMT

Rawalpindi – PK

Munira Moosajee

The Aga Khan Univeristy Hospital

Karachi – PK

\\ Abstracts //

  • Day 1
  • Irum Khan
    Irum Khan 1700-1730

    1. Abstract # 333. Efficacy and safety of Venetoclax in combination with Gilteritinib for R/R FLT3-mutated AML in the expansion cohort of a phase 1b. Daver et al.
    2. Abstract # 693: Outcomes of TP53 mutant AML with Venetoclax and Decitabine. Kim et al.

  • Salman Fazal
    Salman Fazal 1730-1800

    1. Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Bas eline Erythropoietin Levels
    2. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

  • Vahid Afshar Kharghan
    Vahid Afshar Kharghan 1830-1900

    1. Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
    2. A Retrospective Cohort Study Evaluating the Safety and Efficacy of Peri-Partum Tranexamic Acid for Women with Inherited Bleeding Disorders

  • Shabeeha Rana
    Shabeeha Rana 1925-1955

    1. Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial
    2. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

  • Day 2
  • Mohammad Salman Faisal
    Mohammad Salman Faisal 1700-1705

    Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

  • Tanya Siddiqi
    Tanya Siddiqi 1705-1735

    1. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
    2. Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

  • Sairah Ahmed
    Sairah Ahmed 1800-1830

    1. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    2. Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

  • Jasmine Zain
    Jasmine Zain 1830-1900

    1. Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-
    2 and/or BCL-6 Gene Rearrangements or Increase Copy Number 2.Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

  • Naseema Gangat
    Naseema Gangat 1930-2000

    1. Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms
    2. abstract 481 long term use of ropeginterferon alpha 2b in PV 5 year results from a randomized controlled study

  • Day 3
  • Qamar un nisa Chaudhry
    Qamar un nisa Chaudhry 1700-1720

    1.A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: (FluCAB-Prime)
    2. Disease Progression and Outcomes in Patients with Telomere Biology Disorders

  • Hamza Hashmi
    Hamza Hashmi 1740-1810

    1. Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
    2. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
    3. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
    4. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

  • Damiano Rondelli
    Damiano Rondelli 1840-1910

    1. Safety and efficacy of CTX001 in patients with transfusion-dependent beta-thalassemia and sickle cell disease: early results from the Climb THAL-111 and Climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells

  • Shahrukh K Hashmi
    Shahrukh K Hashmi 1930-2000

    1. Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213
    2. REACH 3 trial: Ruxolitinib for cGVHD 3. Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Contact Us

If you have any questions about the event or the team of lecturers, please send us a message and we will reply shortly.

For more information and details, contact our customer service

Conference Secretariat:
AFBMTC/NIBMT, CMH Medical Complex, Rawalpindi – Pakistan
Tel: +92 51 9270076 Ext 228, Cell & WhatsApp: +92 322 5181302, +92 310 2500292
Email: WBMT2022Pakistan@gmail.com